Oruka Therapeutics, Inc.
ORKA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $847 | $473 | $428 | $326 |
| - Cash | $91 | $65 | $84 | $62 |
| + Debt | $2 | $2 | $1 | $1 |
| Enterprise Value | $758 | $410 | $345 | $265 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$30 | -$25 | -$21 | -$37 |
| % Margin | – | – | – | – |
| Net Income | -$30 | -$25 | -$21 | -$33 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.69 | -0.58 | -0.5 | -1.54 |
| % Growth | -19% | -16% | 67.5% | – |
| Operating Cash Flow | -$22 | -$23 | -$21 | -$19 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$22 | -$23 | -$21 | -$19 |